(Rac)-T6167923

(Rac)-T6167923 (0-20 µg/mL; 30 min preincubation, 24 h infection) decreases iNOS, TNF-α, and IL-8 expression and modulates MMR expression in PMA-differentiated THP-1 macrophages; at 10 μg/mL, TNF-α and IL-8 expression decrease to 1.15-fold and 1.10-fold, respectively, and MMR increases from 0.71-fold with MAP infection alone to 0.92-fold^[1].
(Rac)-T6167923 (10 μg/mL; MAP infection; 24 h) reduces iNOS and IL-8 expression to levels comparable to those in uninfected cells in THP-1-derived macrophages, while promoting M2-related MMR expression and increasing IL-10; under combined conditions, IL-10 increases 2.5-fold compared with MAP infection alone^[1].
(Rac)-T6167923 (10 μg/mL; MAP infection; 48 h) reduces intracellular MAP survival to 55% at 48 h in THP-1-derived macrophages^[1].
(Rac)-T6167923 (1-500 μM; PAM3CSK4 (HY-P1180) 100 ng/mL; 24 h) concentration-dependently inhibits NF-κB activation in RAW-Blue macrophages; at 100 and 500 μM, NF-κB activation is reduced by 40% and 50%, respectively^[2].
(Rac)-T6167923 (0.05-200 μM; PAM3CSK4 50 ng/mL; 8 h) decreases IL-6 production in a concentration-dependent manner in RAW 264.7 macrophages; at 100 μM it reduces IL-6 by 89%, and at 150 and 200 μM IL-6 levels decrease by 15-fold and 19-fold, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.